Korea Stem Cell Bank Co., Ltd. agreed to acquire Samsung Medicos Co., Ltd. from SAMSUNG PHARM. Co., LTD. (KOSE:A001360) for KRW 16.3 billion on October 31, 2017. Under the terms of the transaction, SAMSUNG PHARM. Co., LTD. will sell 3.8 million shares of Samsung Medicos Co., Ltd. The entire payment was paid by the series 3 convertible bond Korea Stem Cell Bank Co., Ltd. issued on October 31, 2017. The transaction price has been fully paid on the contract signing date. For the year ended June 30, 2017, Samsung Medicos Co., Ltd. reported total revenues of KRW 896.567 million, total assets of KRW 15.736 billion, net loss of KRW 1.591 billion and net assets of KRW 12.548 billion. Board of Directors resolved the transaction on October 31, 2017. The transaction is expected to complete on October 31, 2017. Han Kyung Accounting Corporation acted as the external rating institution.